Redefining Precision Medicine

Shape the future of precision medicine to improve the quality of life of millions of patients worldwide

Foundations for success

Our Proposal

At GeneproDX, we combine genomics and artificial intelligence to transform cancer diagnosis into a simple and fast process. Our goal is to provide diagnostic certainty, optimizing cancer treatment, reducing costs and avoiding unnecessary therapies. Thanks to our innovative tests, patients and doctors can make decisions based on precise and timely diagnoses.

Our Mission

Our mission at GeneproDX is to provide physicians and patients worldwide with the highest standard of precision medicine for indeterminate thyroid nodules through our innovative solution, ThyroidPrint®.

Our Vision

At GeneproDX, our vision is to pioneer and lead global diagnostic solutions for patients with indeterminate thyroid nodules, continually driving innovation and maintaining the highest quality standards. We strive to help physicians worldwide resolve uncertainty in patient care by harnessing the power of Artificial Intelligence in molecular testing.


Startup and research

A research group led by Dr. Hernán González is formed at the Oncology Laboratory of the School of Medicine at the Pontifical Catholic University of Chile.

In 2007, he participated in an entrepreneurship program in Silicon Valley, presenting his thyroid cancer detection test. Despite initial setbacks, he pursued funding from Corfo and BMRC for the development and validation of the ThyroidPrint® test in biotechnology.

Clinical Studies Consolidation

2017 - Publication of the prototype development of the test, with a cohort of 1,300 patients in Chile:

"Thyroid 2017 Aug. 27(8): 1058-1067. Doi: 10.2089thy 2017.0067"


In 2019, the technology used by ThyroidPrint® was patented. This patent has been granted in Europe, the United States, Canada, Brazil, China, South Korea, Japan, Australia, and South Africa.

2020 - 2021
The COVID-19 pandemic began

Due to the pandemic, GeneproDX partnered with the Pontifical Catholic University of Chile's "Proyecto Esperanza" for SARS-CoV-2 detection. This made GeneproDX an authorized lab by the Ministry of Health and expanded its services to respiratory patients under the GENEPRO brand. They offered COVID-19 testing until December 31, 2022.

GeneproDX at present

Starting from mid-2022, GeneproDX resumed the centralized service for the ThyroidPrint® test until the present date.

Mapping Our Future: Reaching the Whole World

In GeneproDX, our passion for innovation and positive impact on health drives us to make a global difference. We look towards a promising future, making genetic medicine accessible to all and empowering individuals with valuable information to enhance their lives.

Our Technology

ThyroidPrint® was developed to predict benignity of indeterminate thyroid nodules using an innovative microfluidics real-time PCR technology and a neural network-based algorithm analysis. ThyroidPrint® is able to safely forgo unnecessary diagnostic thyroid surgery in 2/3rd of patients.

It provides the following performance parameters: Sensitivity 91%, Specificity 88%, Negative Predictive Value 95% and Positive Predictive Value of 78%

Our partnership with Biocartis®

Thanks to the partnership between GeneproDX and Biocartis®, ThyroidPrint® becomes the world’s only decentralized molecular test for thyroid nodules through the Idylla™ platform, allowing hospitals to conduct the analysis directly on-site.

How does it work

Step 1

Scan sample & Cartridge

Step 2

Insert Sample in the Cartridge

Step 3

Insert cartridge in the Idylla™ System
and obtain the result within 3 hours

Time Saved

First-of-its-kind Molecular Test: Analyzed in the Hospital in Less Than 3 Hours


ThyroidPrint® can be analyzed directly in hospitals equipped with the Idylla™ platform.


Available globally thanks to Biocartis® presence in over 88 countries.

World Presence

At GeneproDX, we are leading a global revolution in reclassify indeterminate thyroid nodules diagnostics. Our cutting-edge technology is expanding our presence beyond Europe and Latin America. Over the next two years, our determination and our descentralized model through Idylla™ Platform will take us to every corner of the world, providing patients and doctors with fast and accurate results.

Join us in creating a future where innovative tests unlock the answers to critical clinical questions, transforming treatment decisions and saving thyroids. Together, let's conquer the world avoiding thyroid unnecessary surgeries!

Contact us any time

Contact us for more information or to arrange a meeting.
Let's shape the future of precision medicine together.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.